Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 8 for:    Reserpine

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00267657
Recruitment Status : Unknown
Verified December 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
First Posted : December 21, 2005
Last Update Posted : January 11, 2017
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)

Tracking Information
First Submitted Date  ICMJE December 20, 2005
First Posted Date  ICMJE December 21, 2005
Last Update Posted Date January 11, 2017
Study Start Date  ICMJE January 2004
Primary Completion Date Not Provided
Current Primary Outcome Measures  ICMJE
 (submitted: October 25, 2007)
  • Craving
  • Cardiovascular
  • Subjective symptoms/Mood Effects
  • CNS norepinephrine turnover
Original Primary Outcome Measures  ICMJE
 (submitted: December 20, 2005)
  • Craving
  • Cardiovasular
  • Subjective symptoms/Mood Effects
  • CNS norepinephrine turnover
Change History Complete list of historical versions of study NCT00267657 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Outcome Measures  ICMJE Not Provided
Original Other Outcome Measures  ICMJE Not Provided
 
Descriptive Information
Brief Title  ICMJE A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1
Official Title  ICMJE Assessment of Interactions Between IV Methamphetamine and Reserpine
Brief Summary In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Detailed Description In this parallel group clinical pharmacology laboratory experiment, we will assess pharmacodynamic interactions (with a focus on cardiovascular effects) of a 15 mg intravenous methamphetamine dose and single oral doses of reserpine (0.5 and 1.0 mg) or placebo.
Study Type  ICMJE Interventional
Study Phase Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Amphetamine-Related Disorders
Intervention  ICMJE Drug: Reserpine
Study Arms Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Unknown status
Enrollment  ICMJE
 (submitted: December 20, 2005)
30
Original Enrollment  ICMJE Same as current
Study Completion Date November 2004
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Please contact site for more details

Exclusion Criteria:

  • Please contact site for more details
Sex/Gender
Sexes Eligible for Study: All
Ages 21 Years to 45 Years   (Adult)
Accepts Healthy Volunteers No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00267657
Other Study ID Numbers  ICMJE NIDA-CPU-0006-1
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE National Institute on Drug Abuse (NIDA)
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Reese Jones, M.D. Langley Porter Psychiatric Institute
PRS Account National Institute on Drug Abuse (NIDA)
Verification Date December 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP